Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.
Stocks · News reference
Adicet Bio shares are trading lower after the company announced safety and efficacy data from the Phase 1 study evaluating prulacabtagene leucel as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $34
HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $27 to $34.
8-K filing — Adicet Bio, Inc. (ACET)
Filed: 2026-09-28 AccNo: 0001720580-26-000060 Size: 15 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits